Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary
thrombotic thrombocytopenic purpura, a lethal microvascular condition resulting from …

COVID-19 is an ongoing public health emergency that has affected millions of people
worldwide and is still a threat to many more. One of the pathophysiological features of …

Background and aims Endothelial dysfunction and portal hypertension (PH) are reflected by
increased von Willebrand factor antigen (VWF-Ag) levels in advanced chronic liver disease …

Background and aims In cirrhosis, decreased portal flow velocity, thrombophilia factors, and
portal hypertension are considered risk factors for portal vein thrombosis (PVT). In cirrhosis …

Abstract Background Von Willebrand factor antigen (VWF) is a non-invasive marker for
clinically significant portal hypertension (HVPG≥ 10 mmHg) and confers HVPG …

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)
continues to rise, making it one of the most prevalent chronic liver disorders. MASLD …

The von Willebrand factor (vWF) is best known for its role in the hemostatic pathway, aiding
platelet adhesion and aggregation, as well as circulating along with coagulation factor VIII …

Background: Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are
characterized by systemic inflammation and high mortality, but there is no effective clinical …

Background Serum concentrations of 25‐hydroxyvitamin D (25 (OH) VD) and C‐reactive
protein (CRP) and von Willebrand's factor (vWF) concentration correlate with histopathologic …

Acute hepatic dysfunction is categorized as acute liver injury (ALI) ie presence of
coagulopathy, with no encephalopathy and acute liver failure (ALF) ie, presence of …